Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.

Wiesman C, Rose E, Grant A, Zimilover A, Klugman S, Schreiber-Agus N.

Genet Med. 2017 May;19(5):529-536. doi: 10.1038/gim.2016.154. Epub 2016 Oct 13.

PMID:
27735926
2.

From Campers to Counselors: a Resource for Prospective Genetic Counseling Students.

Wiesman C, Rose E, Klugman S, Schreiber-Agus N.

J Genet Couns. 2016 Aug;25(4):658-63. doi: 10.1007/s10897-015-9915-8. Epub 2015 Nov 27.

PMID:
26611540
3.

Challenges of Pre- and Post-Test Counseling for Orthodox Jewish Individuals in the Premarital Phase.

Rose E, Schreiber-Agus N, Bajaj K, Klugman S, Goldwaser T.

J Genet Couns. 2016 Feb;25(1):18-24. doi: 10.1007/s10897-015-9880-2. Epub 2015 Sep 10.

PMID:
26354339
4.

The Ashkenazi Jewish carrier screening panel: evolution, status quo, and disparities.

Hoffman JD, Park JJ, Schreiber-Agus N, Kornreich R, Tanner AK, Keiles S, Friedman KJ, Heim RA.

Prenat Diagn. 2014 Dec;34(12):1161-7. doi: 10.1002/pd.4446. Epub 2014 Jul 31. Review.

PMID:
24996053
5.

Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

Barrett MJ, Shanker VL, Severt WL, Raymond D, Gross SJ, Schreiber-Agus N, Kornreich R, Ozelius LJ, Bressman SB, Saunders-Pullman R.

JIMD Rep. 2014;16:31-8. doi: 10.1007/8904_2014_315. Epub 2014 May 22.

6.

Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze.

Ferreira JC, Schreiber-Agus N, Carter SM, Klugman S, Gregg AR, Gross SJ.

Am J Obstet Gynecol. 2014 Sep;211(3):197-204. doi: 10.1016/j.ajog.2014.02.001. Epub 2014 Feb 5. Review.

PMID:
24508465
7.

Detection of carriers in the Ashkenazi Jewish population: an objective comparison of high-throughput genotyping versus gene-by-gene testing.

Klugman S, Schreiber-Agus N, Nazareth S, Evans EA.

Genet Test Mol Biomarkers. 2013 Oct;17(10):763-7. doi: 10.1089/gtmb.2013.0105. Epub 2013 Aug 17.

PMID:
23952016
8.

The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, Gana-Weisz M, Raymond D, Rozenkrantz L, Deik A, Gurevich T, Gross SJ, Schreiber-Agus N, Giladi N, Bressman SB, Orr-Urtreger A.

Neurology. 2013 Apr 23;80(17):1606-10. doi: 10.1212/WNL.0b013e31828f180e. Epub 2013 Mar 27.

9.

Platelet hexosaminidase a enzyme assay effectively detects carriers missed by targeted DNA mutation analysis.

Nakagawa S, Zhan J, Sun W, Ferreira JC, Keiles S, Hambuch T, Kammesheidt A, Mark BL, Schneider A, Gross S, Schreiber-Agus N.

JIMD Rep. 2012;6:1-6. doi: 10.1007/8904_2011_120. Epub 2012 Jan 31.

10.

Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Barrett MJ, Hagenah J, Dhawan V, Peng S, Stanley K, Raymond D, Deik A, Gross SJ, Schreiber-Agus N, Mirelman A, Marder K, Ozelius LJ, Eidelberg D, Bressman SB, Saunders-Pullman R; LRRK2 Ashkenazi Jewish Consortium.

Parkinsonism Relat Disord. 2013 Feb;19(2):186-91. doi: 10.1016/j.parkreldis.2012.09.007. Epub 2012 Oct 10.

11.

Rapid and novel prenatal molecular assay for detecting aneuploidies and microdeletion syndromes.

Gross SJ, Bajaj K, Garry D, Klugman S, Karpel BM, Roe AM, Wagner BJ, Zhan J, Apfelroth SD, Schreiber-Agus N.

Prenat Diagn. 2011 Mar;31(3):259-66. doi: 10.1002/pd.2674. Epub 2011 Jan 4.

PMID:
21207408
12.

Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing.

Schneider A, Nakagawa S, Keep R, Dorsainville D, Charrow J, Aleck K, Hoffman J, Minkoff S, Finegold D, Sun W, Spencer A, Lebow J, Zhan J, Apfelroth S, Schreiber-Agus N, Gross S.

Am J Med Genet A. 2009 Nov;149A(11):2444-7. doi: 10.1002/ajmg.a.33085.

PMID:
19876898
13.

Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines.

Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A.

Cancer Res. 2008 Sep 15;68(18):7258-63. doi: 10.1158/0008-5472.CAN-08-0344.

14.

Rybp interacts with Hippi and enhances Hippi-mediated apoptosis.

Stanton SE, Blanck JK, Locker J, Schreiber-Agus N.

Apoptosis. 2007 Dec;12(12):2197-206.

PMID:
17874297
15.

Differential effects of Mxi1-SRalpha and Mxi1-SRbeta in Myc antagonism.

Dugast-Darzacq C, Grange T, Schreiber-Agus NB.

FEBS J. 2007 Sep;274(17):4643-53. Epub 2007 Aug 14.

16.

Rybp, a polycomb complex-associated protein, is required for mouse eye development.

Pirity MK, Wang WL, Wolf LV, Tamm ER, Schreiber-Agus N, Cvekl A.

BMC Dev Biol. 2007 Apr 30;7:39.

17.

The Polycomb-associated protein Rybp is a ubiquitin binding protein.

Arrigoni R, Alam SL, Wamstad JA, Bardwell VJ, Sundquist WI, Schreiber-Agus N.

FEBS Lett. 2006 Nov 13;580(26):6233-41. Epub 2006 Oct 19. Erratum in: FEBS Lett. 2006 Dec 11;580(28-29):6754.

18.

Yaf2 inhibits caspase 8-mediated apoptosis and regulates cell survival during zebrafish embryogenesis.

Stanton SE, McReynolds LJ, Evans T, Schreiber-Agus N.

J Biol Chem. 2006 Sep 29;281(39):28782-93. Epub 2006 Aug 4.

19.

Lessons learned from Myc/Max/Mad knockout mice.

Pirity M, Blanck JK, Schreiber-Agus N.

Curr Top Microbiol Immunol. 2006;302:205-34. Review.

PMID:
16620030
20.

Rybp/DEDAF is required for early postimplantation and for central nervous system development.

Pirity MK, Locker J, Schreiber-Agus N.

Mol Cell Biol. 2005 Aug;25(16):7193-202.

21.

Mxi1-SRalpha: a novel Mxi1 isoform with enhanced transcriptional repression potential.

Dugast-Darzacq C, Pirity M, Blanck JK, Scherl A, Schreiber-Agus N.

Oncogene. 2004 Nov 25;23(55):8887-99.

PMID:
15467743
22.

Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice.

Scherl A, Li JF, Cardiff RD, Schreiber-Agus N.

Prostate. 2004 Jun 1;59(4):448-59.

PMID:
15065094
23.

Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism.

Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A, Lisanti MP.

Biochemistry. 2001 Mar 20;40(11):3354-62.

PMID:
11258956
24.

Disruption of the Cockayne syndrome B gene impairs spontaneous tumorigenesis in cancer-predisposed Ink4a/ARF knockout mice.

Lu Y, Lian H, Sharma P, Schreiber-Agus N, Russell RG, Chin L, van der Horst GT, Bregman DB.

Mol Cell Biol. 2001 Mar;21(5):1810-8.

25.

Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery.

Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA.

Science. 2000 Feb 18;287(5456):1253-8.

26.

Gene-target recognition among members of the myc superfamily and implications for oncogenesis.

O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, Schwab R, Alland L, Thomson C, Ronning DR, Sacchettini JC, Meltzer P, DePinho RA.

Nat Genet. 2000 Feb;24(2):113-9.

PMID:
10655054
27.

Mouse models of prostate cancer.

Sharma P, Schreiber-Agus N.

Oncogene. 1999 Sep 20;18(38):5349-55. Review.

28.

Repression by the Mad(Mxi1)-Sin3 complex.

Schreiber-Agus N, DePinho RA.

Bioessays. 1998 Oct;20(10):808-18. Review.

PMID:
9819568
29.

Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth.

Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA.

Nature. 1998 Jun 4;393(6684):483-7.

PMID:
9624006
30.

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Pomerantz J, Schreiber-Agus N, LiƩgeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA.

Cell. 1998 Mar 20;92(6):713-23.

31.

An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts.

Orr MS, Reinhold W, Yu L, Schreiber-Agus N, O'Connor PM.

J Biol Chem. 1998 Feb 13;273(7):3803-7.

32.

Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.

Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1392-7.

33.

Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.

Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N, DePinho RA.

Nature. 1997 May 1;387(6628):49-55.

PMID:
9139821
34.

Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype.

Schreiber-Agus N, Stein D, Chen K, Goltz JS, Stevens L, DePinho RA.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1235-40.

35.

A biochemical and biological analysis of Myc superfamily interactions.

Schreiber-Agus N, Alland L, Muhle R, Goltz J, Chen K, Stevens L, Stein D, DePinho RA.

Curr Top Microbiol Immunol. 1997;224:159-68. Review. No abstract available.

PMID:
9308239
36.

Functional interactions among members of the Myc superfamily and potential relevance to cutaneous growth and development.

Chin L, LiƩgeois N, DePinho RA, Schreiber-Agus N.

J Investig Dermatol Symp Proc. 1996 Apr;1(2):128-35. Review.

PMID:
9627706
37.

Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.

Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA.

Oncogene. 1996 Mar 7;12(5):1165-72.

PMID:
8649810
38.

Contrasting roles for Myc and Mad proteins in cellular growth and differentiation.

Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, Cordon-Cardo C, DePinho RA.

Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8488-92.

39.

Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells.

Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD.

Nat Med. 1995 Jul;1(7):638-43.

PMID:
7585143
40.

An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3.

Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA.

Cell. 1995 Mar 10;80(5):777-86.

41.

Contrasting roles for c-Myc and L-Myc in the regulation of cellular growth and differentiation in vivo.

Morgenbesser SD, Schreiber-Agus N, Bidder M, Mahon KA, Overbeek PA, Horner J, DePinho RA.

EMBO J. 1995 Feb 15;14(4):743-56.

42.

Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: the zebra fish homolog of Mxi1.

Schreiber-Agus N, Chin L, Chen K, Torres R, Thomson CT, Sacchettini JC, DePinho RA.

Oncogene. 1994 Nov;9(11):3167-77.

PMID:
7936639
43.

Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1.

Lahoz EG, Xu L, Schreiber-Agus N, DePinho RA.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5503-7.

44.

Zebra fish myc family and max genes: differential expression and oncogenic activity throughout vertebrate evolution.

Schreiber-Agus N, Horner J, Torres R, Chiu FC, DePinho RA.

Mol Cell Biol. 1993 May;13(5):2765-75.

45.

Comparative analysis of the expression and oncogenic activities of Xenopus c-, N-, and L-myc homologs.

Schreiber-Agus N, Torres R, Horner J, Lau A, Jamrich M, DePinho RA.

Mol Cell Biol. 1993 Apr;13(4):2456-68.

46.

Myc and Max: a putative transcriptional complex in search of a cellular target.

Torres R, Schreiber-Agus N, Morgenbesser SD, DePinho RA.

Curr Opin Cell Biol. 1992 Jun;4(3):468-74. Review.

PMID:
1497918
47.

myc family oncogenes in the development of normal and neoplastic cells.

DePinho RA, Schreiber-Agus N, Alt FW.

Adv Cancer Res. 1991;57:1-46. Review. No abstract available.

PMID:
1950701

Supplemental Content

Loading ...
Support Center